The company covers an area of 16.000 sqm, 10.000 of which indoors. This area
also contains the production facilities which are divided into the following areas:
veterinary medicines production area
medicines containing beta-lactamics production area
vitamin premixes production area.
This subdivision has been effected in the interests of optimizing plant management,
which, in turn ensures production integrity and consequent product quality.
In compliance with current legislation and European GMP norms, the facilities
are regularly inspected and authorised for production by the health authorities.
The production unit and research group work together and have developed and patented
technologically innovative products.
The technology used by TRE I for the production of these products means the active
ingredients for medicated premixes and vitamin additives are of a higher quality
and are available in a greater quantity, leading to better and more effective
therapies, on the one hand, and to ruminants’ food requirements being supplemented
more efficiently, on the other.
The MLP (Multi Layer Protection) technology used to create the premix for medical
food is another innovative TRE I production method.
This technology means that granular products can be produced which have a constant
granular size; this feature facilitates the mixability of the products in the
feedstuffs, cuts down dust emissions and also contributes to reducing the cross-contamination
typical of feedstuff production plants.
An area dedicated to the production of medicines containing beta-lactamics with
plants equipped with cutting-edge technological equipment and devices, all of
which certified and inspected in accordance with GMP has also been created as
part of the production facilities.
Finished products are stored separately and managed in such a way that guarantees
both speed and quality in delivery, once the QA/QC division releases them for
sale.
